Biogen said total revenue for Q1 2024 was $2,290.5 million, down 7% from $2,463.0 million a year earlier. GAAP diluted EPS was $2.70, and Non-GAAP diluted EPS was $3.67.

1. 01

   Biogen said total revenue for Q1 2024 was $2,290.5 million, down 7% from $2,463.0 million a year earlier. GAAP diluted EPS was $2.70, and Non-GAAP diluted EPS was $3.67.

2. 02

   The company said LEQEMBI global in-market sales for Q1 were approximately $19 million, nearly 3 times the level of Q4 2023. It also said SKYCLARYS global revenue for Q1 was $78 million.

3. 03

   Biogen said GAAP R&D expense for Q1 was $452.9 million, down from $570.6 million a year earlier. It cited savings from its Fit for Growth and R&D portfolio prioritization initiatives as the reason for the decrease. The company also said GAAP operating income rose 10% and Non-GAAP operating income rose 24%.

4. 04

   The company said net cash flow from operations for Q1 was $553 million, and free cash flow was $507 million. It also said it reaffirmed its full-year Non-GAAP diluted EPS guidance of $15.00 to $16.00.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.